glp-1 parkinson's disease lancet Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative treatment GLP-1 Signalling as a Therapeutic
Description
Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox
Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation
Other Demen 30 (5), 478487
In 2025 Boccard partnered with a pharmaceutical manufacturer to design and deliver a complete GLP1 production installation supporting the clients expansion plan
Some prefer weekly injections while others prefer a [daily] pill
